Myriad Genetics (NASDAQ:MYGN) shares rose 3.7% after signing an exclusive deal with Zydus Lifesciences to offer cancer tests in India. The partnership aims to expand precision oncology services for Indian patients, improving risk assessment and treatment planning. Despite the initial spike, shares settled at $6.80. The market views this news as significant but not game-changing. Myriad Genetics has been volatile, with 42 moves over 5% in the past year. The company recently presented data on its cancer tests at a symposium. Shares are down 49.7% this year and trading 54.6% below their 52-week high.

Read more at StockStory: Myriad Genetics (MYGN) Stock Trades Up, Here Is Why